Nori Wassan, Akram Nabeeha Najatee, Al-Ani Raid M
Department of Obstetrics and Gynecology, Mustansiriyah University, Baghdad 10052, Iraq.
Department of Pediatrics, Mustansiriyah University, Baghdad 10052, Iraq.
World J Exp Med. 2023 Sep 20;13(4):99-101. doi: 10.5493/wjem.v13.i4.99.
It is well-known that hydroxychloroquine (HCQ) treats malaria, systemic lupus erythematosus, and rheumatoid arthritis in women for its immunomodulatory and anti-inflammatory action. Additionally, HCQ was used in cases with refractory antiphospholipid syndrome. HCQ safety was reinforced in pregnant women owing to insignificant reports of adverse pregnancy outcomes and major congenital malformation. Recently, HCQ was tested in cases with chronic placental inflammation with a promising result of increased life birth; however, its benefit needs further validation. We aimed to highlight the recent updates for HCQ use in various conditions in pregnancy.
众所周知，羟氯喹（HCQ）因其免疫调节和抗炎作用，可用于治疗女性疟疾、系统性红斑狼疮和类风湿性关节炎。此外，HCQ还用于治疗难治性抗磷脂综合征。由于关于不良妊娠结局和主要先天性畸形的报告较少，HCQ在孕妇中的安全性得到了加强。最近，HCQ在慢性胎盘炎症病例中进行了测试，结果显示活产率有所提高，前景乐观；然而，其益处仍需进一步验证。我们旨在强调HCQ在孕期各种情况下使用的最新进展。
